Cancer vaccines, a critical review - Part I

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 140-149

  Mitchell, Malcolm S ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccine; CancerVax; Interferon; M vax; Melacine; T cell; Tumor

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; B7 ANTIGEN; BCG VACCINE; CANCER VACCINE; COLON CARCINOMA VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; DINITROPHENYLHAPTEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B7 ANTIGEN; INTERLEUKIN 2; M VAX; MELACINE; MELANOMA VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE;

ACTIVE IMMUNIZATION; ALLELE; CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL; COLON CARCINOMA; DOSE RESPONSE; DRUG EXPOSURE; DRUG SPECIFICITY; GENETIC TRANSDUCTION; HLA SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INJECTION SITE; IRRADIATION; LYMPH NODE METASTASIS; MELANOMA; META ANALYSIS; METASTASIS; NONHUMAN; PHENOTYPE; REVIEW; SKIN MANIFESTATION; SURVIVAL TIME; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR RECURRENCE; ANIMAL; IMMUNOLOGY; NEOPLASM;

ANIMAL; CANCER VACCINES; HUMAN; MELANOMA; NEOPLASMS; ANIMALS; HUMANS;

EID: 0035985655     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. The origin and functions of natural killer cells
2. Treatment of human melanoma with a hapten-modified autologous vaccine
3. Viral oncolysate in the management of malignant melanoma. II. Clinical studies
4. Vaccinia viral lysates in treatment of melanoma
5. Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene
6. The discovery of MHC restriction
7. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma
8. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients
9. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases
10. Effectiveness of autologous, hapten-modified melanoma vaccine depends on the timing of an induction doses
11. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial
12. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant
13. Active-specific immunotherapy for melanoma
14. Increased effectiveness of interferon-alfa 2b following active specific immunotherapy for melanoma
15. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-α
16. Association of HLA phenotype with response to active specific immunotherapy of melanoma
17. Significant impact of HLA class I alleles on outcome in T3NO melanoma patients treated with Melacine (MEL): An allogenic melanoma cell lysate vaccine: Prospective analysis of Southwestern Oncology Group (SWOG)-9035
18. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
19. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model
20. Active specific immunotherapy as an adjunct to the treatment of metastatic solid tumors
21. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: First randomized phase III trials show promise
22. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
23. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity
24. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
25. Role of neutrophils and CD4+ T-lymphocytes in the primary and memory response to non-immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene
26. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma
27. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ-interferon gene
28. Augmentation of in vivo cytotoxic T-lymphocyte activity and reduction of tumor growth by large multivalent immunogen
29. Phase I trial of large multivalent immunogen (LMI) derived from melanoma lysates in patients with disseminated melanoma
30. Protection against experimental cerebral metastases of murine melanoma B16 by active immunization
31. Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines
32. Cancer immunotherapy by antisense suppression of lipoprotein in MHC-class-II-positive tumor cells